Pharming Group N.V. reiterates it commitment to the treatment of rare diseases on Rare Disease Day 2016, an annual global initiative committed to improving public understanding of rare diseases and highlighting the exceptional challenges facing patients and their carers.
Nearly 7,000 different rare diseases have been identified to date, directly affecting the daily life of more than 60 million people in Europe and the US alone. Today, people living with or affected by a rare disease, patient organisations, politicians, carers, medical professionals, researchers and industry will come together in solidarity to raise awareness of rare diseases.
Pharming developed Ruconest, currently marketed in the US and EU, for the treatment of HAE attacks. Ruconest is also in development for paediatric use and for prophylaxis of HAE.
Sijmen de Vries, Pharming’s CEO, commented: “Pharming supports Rare Disease Day to recognise the many patients around the world living with the burden of such diseases. As an R&D company, we are working diligently, through our technology platform, to find new solutions. Through Ruconest, we are providing a safe and efficacious non-blood derived (recombinant) enzyme replacement therapy for HAE patients in countries where the treatment is approved and available and through the HAEi Global Access Plan in the rest of the world.”
Rare Disease Day was launched by EURORDIS (The European Organisation for Rare Disorders) and it’s Council of National Alliances in 2008. Held on the last day of February each year, it seeks to raise awareness of the impact that rare diseases have on the lives of patients and those who care for them. The campaign began as a European event but has quickly become international in scope, with the US joining in 2009, and participation in over 80 countries around the world in 2015.
For more information, please visit www.rarediseaseday.org.
(Source: Pharming)
